As innovative medicines become more widely covered in workplace drug plans, employers are tasked with finding new ways to control costs while ensuring members receive the best value. “Obviously, this is good because such offers provide more treatments for employees and their families that can help get them back to the workplace sooner rather than […]
Canadian employers are making ongoing changes to their pension and benefits offerings as the coronavirus pandemic drags on, according to a new survey by the International Foundation of Employee Benefit Plans. The survey found almost one in five (18 per cent) employers offering prescription drug coverage have extended the time allowed under prior authorization periods, […]
The New Brunswick government is expanding the use of biosimilars for certain chronic conditions in its public drug plans. Approximately 3,000 beneficiaries of the province’s drug plans who are living with diseases such as inflammatory arthritis, inflammatory bowel disease, diabetes and psoriasis will have until Nov. 30 to switch from a biologic to the biosimilar […]
While a national pharmacare program is yet to be revealed by the federal government, any future plan should contain provisions for all costly treatments and not just rare diseases, says Jennifer Schmidt, a principal at Mercer Canada. Read: Federal budget highlights national childcare system, extension of pandemic subsidies This week’s federal budget announcement contained only […]
While drug plan costs are increasing for plan sponsors, the causes for these increases may depend on which part of Canada a plan sponsor resides in, says Philippe Laplante, a principal responsible for the group benefits practice in Eckler Ltd.’s Montreal office. Over the past three years in Quebec, the average annual increase of recommended pricing […]
In its 2020 budget submission to the Ontario government, the Canadian Life and Health Insurance Association is highlighting a lack of access to affordable prescription drugs and inflexible pension plans. With respect to prescription drugs, the CLHIA noted it supports the federal Patented Medicine Prices Review Board reforms, which were introduced on Friday. “It is crucial that the […]
While medical cannabis coverage is appearing in more benefits plans, most insurers that cover it still have very specific conditions. Sun Life Canada covers the most conditions, at seven, after adding two ailments to its roster in 2019. Marie-Chantal Côté, the insurer’s vice-president of market development for group benefits, says evidence is emerging that shows […]
An upcoming Sun Life Canada drug plan change that will be implemented outside of plan sponsors’ renewal periods is calling attention to the practice of block-level contract amendments. Sun Life is set to implement the first phase of its reference drug program on Oct. 1, which the insurer says will help plan sponsors with drug plan sustainability by creating categories […]
Over the past four years, total drug costs adjudicated by HBM+ have risen from about $1.2 billion to $1.5 billion, while the number of claimants has increased from 1.7 million to more than two million. The inaugural drug trends and strategic insights report by the health benefits manager, a division of Green Shield Canada, examined drug […]
Plan sponsors have to move beyond benefits plan reporting and dig into analytics to better understand medication non-adherence and the top disease states affecting their workforces. “Leveraging plan-specific data can help answer the fundamental questions needed to manage your benefits program,” said Shawn O’Brien, Telus Health’s principal of data enablement and drug, health, dental product roadmaps, during a session at Benefits […]